AG
IONS icon

Artal Group’s Ionis Pharmaceuticals IONS Stock Holding History

Artal Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200,000
Closed -$9.57M – 104
2016
Q4 		$9.57M Hold
200,000
– – 0.21% 37
2016
Q3 		$7.33M Buy
+200,000
New +$6.26M 0.15% 42
2016
Q1 		– Sell
-100,000
Closed -$6.19M – 71
2015
Q4 		$6.19M Hold
100,000
– – 0.12% 60
2015
Q3 		$4.04M Buy
+100,000
New +$5.18M 0.09% 59

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Artal Group's IONS Position: Q3 2017 in Review

Artal Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2017, closing a stake of 135,000 shares — an estimated $6.87M sold.

Artal Group first reported a position in IONS in Q1 2014 and held it in 11 quarters. The position peaked at $25.5M in Q1 2015. 301 funds tracked by Wall St. Rank hold IONS as of Q3 2017.

  • Artal Group reported no remaining Ionis Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Artal Group sold 135,000 Ionis Pharmaceuticals shares in Q3 2017, an estimated $6.87M.
  • Artal Group first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 11 quarters.
  • Artal Group's Ionis Pharmaceuticals position peaked at $25.5M in Q1 2015.
  • 301 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2017.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.